{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:21Z","timestamp":1786649541124,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors improve chronic myeloid leukemia (CML) outcomes. Dasatinib inhibits breakpoint cluster region-Abelson 1 proto-oncogene tyrosine kinase better than imatinib in CML. T-regulatory cells prevent autoimmune diseases and aberrant immune responses by reducing oncoprotein antigen reactivity. They also reduce self-antigen-induced immune responses to maintain peripheral tolerance. In this study, T-regulatory cells in peripheral blood of chronic myeloid leukemia-chronic phase patients were measured, together with serum levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and transforming growth factor (TGF)-\u03b21 at diagnosis and 3 months postdasatinib therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The Pathology and Clinical Haematology Departments at King George\u2019s Medical University, Lucknow, India, conducted this prospective analytical study. Forty CML-chronic patients and 10 healthy controls were analyzed. Flow cytometry was used to determine T-regulatory cell percentage in peripheral blood mononuclear cells of newly diagnosed CML patients before and after 3 months of dasatinib treatment; ELISA was used to measure serum levels of CTLA-4 and TGF-\u03b21.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>T-regulatory cells, CTLA-4, and TGF-\u03b21 significantly decreased in CML-chronic phase patients after 3 months of dasatinib therapy compared to the initial diagnosis. No significant change in T-regulatory cell, CTLA-4, or TGF-\u03b21 percentages were seen between responders and poor responders. However, responders had a lower percentage of T-regulatory cells than suboptimal responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The study concluded that dasatinib treatment improved response in CML patients with decreased Treg cells. Dasatinib reduces Treg-mediated immunological suppression, reducing CTLA-4 and TGF-\u03b21 levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_5_24","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T06:00:14Z","timestamp":1729663214000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-\u03b21 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy"],"prefix":"10.4103","volume":"24","author":[{"given":"Akanksha","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kushwaha","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra Prasad","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahid","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma Shankar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"R1-20260427","doi-asserted-by":"crossref","first-page":"100825.","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"R2-20260427","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"R3-20260427","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"R4-20260427","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1034\/j.1600-065X.2003.00015.x","article-title":"The influence of the SRC-family kinases, Lck and Fyn, on T cell differentiation, survival and activation","volume":"191","author":"Zamoyska","year":"2003","journal-title":"Immunol Rev"},{"key":"R5-20260427","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"key":"R6-20260427","doi-asserted-by":"crossref","first-page":"51.","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"R7-20260427","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3892\/ol.2017.6294","article-title":"Therapeutic immune monitoring of CD4(+) CD25(+) T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"14","author":"Lu","year":"2017","journal-title":"Oncol Lett"},{"key":"R8-20260427","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","article-title":"Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells","volume":"144","author":"Fei","year":"2009","journal-title":"Br J Haematol"},{"key":"R9-20260427","doi-asserted-by":"crossref","first-page":"26.","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol Cancer"},{"key":"R10-20260427","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-018-0083-6","article-title":"Central CD4(+) T cell tolerance: Deletion versus regulatory T cell differentiation","volume":"19","author":"Klein","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"R11-20260427","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2008-01-135335","article-title":"Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura","volume":"112","author":"Yu","year":"2008","journal-title":"Blood"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2007.03.014","article-title":"T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation","volume":"26","author":"Li","year":"2007","journal-title":"Immunity"},{"key":"R13-20260427","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1871523013666141126100019","article-title":"Generation, subsets and functions of inducible regulatory T cells","volume":"13","author":"Kosten","year":"2015","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"R14-20260427","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.semcancer.2022.06.009","article-title":"Natural products and their derivatives as immune check point inhibitors: Targeting cytokine\/chemokine signalling in cancer","volume":"86","author":"Gupta","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R15-20260427","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"R16-20260427","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.htct.2019.03.006","article-title":"Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase","volume":"41","author":"Moura","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"R17-20260427","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.4103\/jfmpc.jfmpc_307_19","article-title":"A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India","volume":"8","author":"Kumar","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"R18-20260427","first-page":"3025","article-title":"Tyrosine kinase inhibitors in Ph+chronic myeloid leukemia therapy: A review","volume":"17","author":"Shah","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"R19-20260427","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the international randomized study of interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"R20-20260427","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"R21-20260427","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"key":"R22-20260427","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10147-013-0615-9","article-title":"Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients","volume":"19","author":"Zahran","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"R23-20260427","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4110\/in.2009.9.6.209","article-title":"The role of regulatory T cells in cancer","volume":"9","author":"Ha","year":"2009","journal-title":"Immune Netw"},{"key":"R24-20260427","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"key":"R25-20260427","doi-asserted-by":"crossref","first-page":"300060519877321.","DOI":"10.1177\/0300060519877321","article-title":"Effects of dasatinib on CD8(+) T, Th1, and Treg cells in patients with chronic myeloid leukemia","volume":"48","author":"Wei","year":"2020","journal-title":"J Int Med Res"},{"key":"R26-20260427","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JBM.S187005","article-title":"Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor \u03b2(1), and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia","volume":"10","author":"Nomura","year":"2019","journal-title":"J Blood Med"},{"key":"R27-20260427","doi-asserted-by":"crossref","first-page":"2912.","DOI":"10.3390\/cancers15112912","article-title":"Chemo-immunotherapy: A new trend in cancer treatment","volume":"15","author":"Sordo-Bahamonde","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_5_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:12Z","timestamp":1786647312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_5_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_5_24","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"2024-01-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}